

**Authors**

Julio Saul Solís Arce  
WZB Berlin Social Science Center

Shana Warren  
Associate Director, Path-to-Scale Research & Research Scientist

Niccoló Meriggi  
International Growth Centre

Alexandra Scacco  
WZB Berlin Social Science Center

Nina McMurry  
WZB Berlin Social Science Center

Maarten Voors  
Wageningen University & Research

Georgiy Syunyaev  
Columbia University

Amyr Malik  
Yale University Institute for Global Health

Dean Karlan  
Northwestern University

Michael Callen  
London School of Economics and Political Science

Matthieu Teachout  
International Growth Centre

Macartan Humphreys  
Columbia University

Mushfiq Mobarak  
Yale University

Saad B. Omer  
Yale University Institute for Global Health

Andrea Guariso  
Trinity College Dublin

Jakob Svensson  
Stockholm University

Matthieu Teachout  
International Growth Centre

Macartan Humphreys  
Columbia University

Saad B. Omer  
Yale University Institute for Global Health

**Staff**

Shana Warren  
Research Scientist for Path-to-Scale Research

Samya Rahman  
Research Analyst

Gloria Ayesiga Eden  
Research Associate

Elliott Collins  
Research Economist and Director of Poverty Measurement

Margarita Rosa Cabra Garcia  
Senior Research Associate

Sofia Jaramillo  
Senior Research Manager

Anthony Kamwesigye  
Associate Research Manager

Gisele Manirabaruta



# **COVID-19 Vaccine Acceptance in Low- And Middle-Income Countries and Recommendations to Increase Uptake**

In a collective effort bringing together 15 studies, researchers from over 30 institutions surveyed over 20,000 individuals between June 2020 and January 2021 on questions regarding respondents' vaccine acceptance and hesitancy and their most trusted sources for vaccination advice. During some surveys, results from COVID-19 vaccine clinical trials had yet to be announced, and during later surveys, governments had started approving vaccines for use. The fast-moving nature of COVID-19 information may change people's perceptions about vaccines by the time they are widely available in low- and middle-income countries (LMICs). Over the past six months, the body of evidence demonstrating the safety and efficacy of available COVID-19 vaccines, which have been given to millions of people, has become clearer. At the same time, severe, but rare, side effects may have undermined public confidence.

July 19, 2021